Trial Profile
A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 705498 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 Jul 2020 This trial is completed (Global End Date: 22 Feb 2007), according to European Clinical Trials Database record.
- 08 Nov 2007 Patient numbers amended from 42 to 1.
- 08 Nov 2007 Status changed from recruiting to discontinued.